Sorrento Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SRNE research report →
Price Chart
About the company
Sorrento Therapeutics, Inc. is a biopharmaceutical company, active in both clinical development and commercial operations, dedicated to creating treatments for a range of serious conditions including cancer, autoimmune disorders, inflammatory diseases, viral infections, and neurodegenerative ailments. The company's operations are divided into two distinct segments: Sorrento Therapeutics and Scilex.
- CEO
- Henry H. Ji
- IPO
- 2007
- Employees
- 949
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on SRNE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $220.51K
- P/E
- -0.00
- Fwd P/E
- 0.00
- PEG
- -0.00
- P/S
- 0.00
- P/B
- -0.01
- EV/EBITDA
- -0.21
- Div Yield
- 0.00%
- Gross Margin
- 46.77%
- Op Margin
- -802.55%
- Net Margin
- -911.60%
- ROE
- -1904.94%
- ROIC
- -286.80%
Latest fiscal year · YoY change
- Revenue
- $62.84M+18.8%
- Gross Profit
- $29.39M-26.3%
- Op Income
- $-504,315,000
- Net Income
- $-572,843,000-33.5%
- EPS
- $-1.37+6.2%
- OCF Growth
- -4.3%
- FCF Growth
- -5.8%
- 52W High
- $0.01
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.13
- RSI (14)
- 51
- Avg Volume
- 133.46K
No earnings-call transcripts are available for SRNE yet.
- Free Float
- 97.8%
- Shares Outstanding
- 551.28M
- Float Shares
- 539.11M
of shares held by institutions
4 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for SRNE, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Highlander Capital Management, LLC | 1.20K | 0 |
Held by 1 ETFs
Biggest fund positions in SRNE by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 17, 23 | Ji Henry | other | 19,500 |
| Mar 17, 23 | Ji Henry | sell | 195 |
| Mar 15, 21 | Janda Kim | sell | 3,000 |
| Dec 31, 21 | Janda Kim | other | 0 |
| Dec 21, 22 | Ji Henry | other | 300 |
| Dec 2, 22 | Ji Henry | other | 200 |
| Dec 2, 22 | Ji Henry | other | 2 |
| Dec 21, 22 | Ji Henry | other | 3 |
| Dec 15, 22 | Ji Henry | other | 1,500,000 |
| Sep 7, 22 | Ji Henry | buy | 88,888 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SRNE coverage
Recent articles, reports, and earnings notes.
No research on SRNE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SRNE report →Sorrento Voyage Announces Expanded Luxury Boat Tours and Proposal Experiences Along the Amalfi Coast
newsfilecorp.com · Jan 5
Sorrento Therapeutics (NASDAQ:SRNE) and Cortexyme (NASDAQ:CRTX) Head to Head Analysis
defenseworld.net · Jan 5
Sorrento Therapeutics (NASDAQ:SRNE) versus NKGen Biotech (NYSE:NKGN) Head-To-Head Review
defenseworld.net · Nov 19
Analyzing Sorrento Therapeutics (SRNEQ) and Its Competitors
defenseworld.net · Oct 31
Financial Survey: Sorrento Therapeutics (SRNEQ) and Its Rivals
defenseworld.net · Oct 26
DSI Introduces Westbury Sorrento Aluminum Railing with Bold Distinctive Mesh Stainless Steel Infills
newsfilecorp.com · Oct 24
Sorrento Resources Announces Appointment of Alex Bugden as President and Chief Executive Officer
newsfilecorp.com · Sep 3
Sorrento Resources to Sell Three Newfoundland Properties to Gold Hunter
newsfilecorp.com · May 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.